AC Immune SA

AC Immune SA, a clinical-stage biopharmaceutical company, is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications.

AC Immune has determined that given the stage of development of its products, its investigational drugs should be studied in patients as part of controlled clinical trials designed to obtain data on safety and efficacy that may be used to support approval of the product and subsequent wider accessibility to patients. We encourage patients to speak with their physicians and to participate in the available clinical trials. At this time, AC Immune cannot provide investigational drug outside of clinical studies. The company will reevaluate this policy when sufficient safety and efficacy information has been obtained in controlled clinical trials.